Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, Sutherland A, Montefiori DC, Girard B, Edwards DK, Feng J, Zhou H, Baden LR, Miller JM, Das R. Chalkias S, et al. N Engl J Med. 2022 Oct 6;387(14):1279-1291. doi: 10.1056/NEJMoa2208343. Epub 2022 Sep 16. N Engl J Med. 2022. PMID: 36112399 Free PMC article. Clinical Trial.
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.
Pajon R, Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, Feng W, Tong J, Eaton A, Maglinao M, Tang H, Manning KE, Edara VV, Lai L, Ellis M, Moore KM, Floyd K, Foster SL, Posavad CM, Atmar RL, Lyke KE, Zhou T, Wang L, Zhang Y, Gaudinski MR, Black WP, Gordon I, Guech M, Ledgerwood JE, Misasi JN, Widge A, Sullivan NJ, Roberts PC, Beigel JH, Korber B, Baden LR, El Sahly H, Chalkias S, Zhou H, Feng J, Girard B, Das R, Aunins A, Edwards DK, Suthar MS, Mascola JR, Montefiori DC. Pajon R, et al. Among authors: chalkias s. N Engl J Med. 2022 Mar 17;386(11):1088-1091. doi: 10.1056/NEJMc2119912. Epub 2022 Jan 26. N Engl J Med. 2022. PMID: 35081298 Free PMC article. No abstract available.
Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.
Shen X, Chalkias S, Feng J, Chen X, Zhou H, Marshall JC, Girard B, Tomassini JE, Aunins A, Das R, Montefiori DC. Shen X, et al. Among authors: chalkias s. N Engl J Med. 2022 Sep 29;387(13):1234-1236. doi: 10.1056/NEJMc2210648. Epub 2022 Sep 9. N Engl J Med. 2022. PMID: 36083119 Free PMC article. No abstract available.
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J, Chen X, Chang Y, Zhou H, Montefiori D, Edwards DK, Girard B, Pajon R, Dutko FJ, Leav B, Walsh SR, Baden LR, Miller JM, Das R. Chalkias S, et al. Nat Med. 2022 Nov;28(11):2388-2397. doi: 10.1038/s41591-022-02031-7. Epub 2022 Oct 6. Nat Med. 2022. PMID: 36202997 Free PMC article. Clinical Trial.
Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination.
Chalkias S, Feng J, Chen X, Zhou H, Marshall JC, Girard B, Tomassini JE, Kuter BJ, Montefiori DC, Das R. Chalkias S, et al. N Engl J Med. 2022 Dec 8;387(23):2194-2196. doi: 10.1056/NEJMc2212772. Epub 2022 Nov 23. N Engl J Med. 2022. PMID: 36416761 Free PMC article. No abstract available.
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT, Cosgrove CA, Moore P, Bethune C, Nally R, Bula M, Kalra PA, Clark R, Dargan PI, Boffito M, Sheridan R, Moran E, Darton TC, Burns F, Saralaya D, Duncan CJA, Lillie PJ, San Francisco Ramos A, Galiza EP, Heath PT, Girard B, Parker C, Rust D, Mehta S, de Windt E, Sutherland A, Tomassini JE, Dutko FJ, Chalkias S, Deng W, Chen X, Feng J, Tracy L, Zhou H, Miller JM, Das R; Study Investigators. Lee IT, et al. Among authors: chalkias s. Lancet Infect Dis. 2023 Sep;23(9):1007-1019. doi: 10.1016/S1473-3099(23)00295-5. Epub 2023 Jun 19. Lancet Infect Dis. 2023. PMID: 37348519 Free article. Clinical Trial.
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A. Budd Haeberlein S, et al. Among authors: chalkias s. J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30. J Prev Alzheimers Dis. 2022. PMID: 35542991 Clinical Trial.
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova EK, Montalban X, Stefoski D, Sprenger T, Robinson RR, Fam S, Smith J, Chalkias S, Giannattasio G, Lima G, Castro-Borrero W. Gold R, et al. Among authors: chalkias s. J Neurol. 2020 Oct;267(10):2851-2864. doi: 10.1007/s00415-020-09835-y. Epub 2020 May 25. J Neurol. 2020. PMID: 32451615 Free PMC article. Clinical Trial.
40 results